Ormeloxifene nanotherapy for cervical cancer treatment

References

• American Cancer Society [homepage on the internet]. Key Statistics for Cervical Cancer; 2019 Available from https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html. Accessed August 8, 2019.
   Google Scholar
• Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17. doi:10.1128/cmr.16.1.1-17.200312525422
   PubMed Web of Science ®Google Scholar
• Reid J. Women’s knowledge of Pap smears, risk factors for cervical cancer, and cervical cancer. J Obstetric Gynecologic Neonatal Nurs. 2001;30(3):299–305. doi:10.1111/j.1552-6909.2001.tb01548.x
   PubMedGoogle Scholar
• Bosch F, Lorincz A, Munoz N, Meijer C, Shah K. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–265. doi:10.1136/jcp.55.4.24411919208
   PubMed Web of Science ®Google Scholar
• Bosch FX, De Sanjosé S. Human papillomavirus and cervical cancer–burden and assessment of causality. J National Cancer Inst Monogr. 2003;Chapter 1(31):3–13. doi:10.1093/oxfordjournals.jncimonographs.a003479
   PubMedGoogle Scholar
• Maglennon GA, Doorbar J. The biology of papillomavirus latency. Open Virol J. 2012;6:1. doi:10.2174/187435790120601019022291864
   PubMedGoogle Scholar
• Castellsagué X, Muñoz N. Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;31:20–28. doi:10.1093/oxfordjournals.jncimonographs.a003477
   PubMedGoogle Scholar
• Brinton LA, Hamman RF, Huggins GR, et al. Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst. 1987;79(1):23–30.3474446
   PubMedGoogle Scholar
• Brinton LA, Schairer C, Haenszel W, et al. Cigarette smoking and invasive cervical cancer. Jama. 1986;255(23):3265–3269.3712678
   PubMed Web of Science ®Google Scholar
• Carter JS, Downs JLS. cervical cancer tests and treatment. Female Patient (Parsippany). 2011;36(1):34.21796233
   PubMedGoogle Scholar
• Janicek MF, Averette HE. Cervical cancer: prevention, diagnosis, and therapeutics. CA Cancer J Clin. 2001;51(2):92–114.11577486
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310–1316. doi:10.1158/1078-0432.CCR-07-144118316549
   PubMed Web of Science ®Google Scholar
• Duyn A, Van Eijkeren M, Kenter G, Zwinderman K, Ansink A. Recurrent cervical cancer: detection and prognosis. Acta Obstet Gynecol Scand. 2002;81(8):759–763.12174162
   PubMed Web of Science ®Google Scholar
• Aubé J. Drug repurposing and the medicinal chemist. ACS Med Chem Lett. 2012;3(6):442–444. doi:10.1021/ml300114c24900492
   PubMed Web of Science ®Google Scholar
• Boguski MS, Mandl KD, Sukhatme VP. Repurposing with a Difference. Science. 2009;324(5933):1394–1395. doi:10.1126/science.116992019520944
   PubMed Web of Science ®Google Scholar
• Singh M. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 2001;21(4):302–347.11410933
   PubMed Web of Science ®Google Scholar
• Lal J. Clinical pharmacokinetics and interaction of centchroman—a mini review. Contraception. 2010;81(4):275–280. doi:10.1016/j.contraception.2009.11.00720227542
   PubMedGoogle Scholar
• Gara RK, Sundram V, Chauhan SC, Jaggi M. Anti-cancer potential of a novel SERM ormeloxifene. Curr Med Chem. 2013;20(33):4177. doi:10.2174/0929867311320999019723895678
   PubMedGoogle Scholar
• Maher DM, Khan S, Nordquist JL, et al. Ormeloxifene efficiently inhibits ovarian cancer growth. Cancer Lett. 2015;356(2):606–612. doi:10.1016/j.canlet.2014.10.00925306892
   PubMedGoogle Scholar
• Khan S, Ebeling MC, Chauhan N, et al. Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Cancer Res. 2015;75(11):2292–2304. doi:10.1158/0008-5472.CAN-14-239725840985
   PubMed Web of Science ®Google Scholar
• Srivastava VK, Gara RK, Bhatt M, Sahu D, Mishra DP. Centchroman inhibits proliferation of head and neck cancer cells through the modulation of PI3K/mTOR pathway. Biochem Biophys Res Commun. 2011;404(1):40–45. doi:10.1016/j.bbrc.2010.11.04921094138
   PubMedGoogle Scholar
• Singh N, Zaidi D, Shyam H, Sharma R, Balapure AK. Polyphenols sensitization potentiates susceptibility of MCF-7 and MDA MB-231 cells to centchroman. PLoS One. 2012;7(6):e37736. doi:10.1371/journal.pone.003773622768036
   PubMedGoogle Scholar
• Hafeez BB, Ganju A, Sikander M, et al. Ormeloxifene suppresses prostate tumor growth and metastatic phenotypes via inhibition of oncogenic β-catenin signaling and EMT progression. Mol Cancer Ther. 2017;16(10):2267–2280. doi:10.1158/1535-7163.MCT-17-015728615299
   PubMedGoogle Scholar
• Chauhan N, Maher DM, Yallapu MM, et al. A triphenylethylene nonsteroidal SERM attenuates cervical cancer growth. Sci Rep. 2019;9(1):10917. doi:10.1038/s41598-019-46680-0
   Google Scholar
• Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56(11):1649–1659. doi:10.1016/j.addr.2004.02.01415350294
   PubMed Web of Science ®Google Scholar
• Thrall JH. Nanotechnology and Medicine 1. Radiology. 2004;230(2):315–318. doi:10.1148/radiol.230203169814752175
   PubMedGoogle Scholar
• Huang Q, Yu H, Ru Q. Bioavailability and delivery of nutraceuticals using nanotechnology. J Food Sci. 2010;75(1):R50–R57. doi:10.1111/j.1750-3841.2009.01457.x20492195
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760. doi:10.1038/nnano.2007.38718654426
   PubMed Web of Science ®Google Scholar
• Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131–135. doi:10.1016/j.addr.2010.03.01120304019
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Part 1):6387–6392.2946403
   PubMed Web of Science ®Google Scholar
• Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev. 2002;54(1):135–147.11755709
   PubMed Web of Science ®Google Scholar
• Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25(10):1165–1170. doi:10.1038/nbt134017891134
   PubMed Web of Science ®Google Scholar
• Ilium L, Davis S, Wilson C, Thomas N, Frier M, Hardy J. Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape. Int J Pharm. 1982;12(2–3):135–146. doi:10.1016/0378-5173(82)90113-2
   Google Scholar
• Moghimi SM, Hedeman H, Muir I, Illum L, Davis SS. An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochimica Et Biophysica Acta (BBA) Gen Subj. 1993;1157(2):233–240. doi:10.1016/0304-4165(93)90105-H
   PubMedGoogle Scholar
• Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharmaceutics Biopharm. 2008;69(1):1–9. doi:10.1016/j.ejpb.2007.08.001
   PubMed Web of Science ®Google Scholar
• Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003;422(6927):37–44. doi:10.1038/nature0145112621426
   PubMed Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Controlled Release. 2005;107(2):215–228. doi:10.1016/j.jconrel.2005.06.006
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci. 2010;351(1):19–29. doi:10.1016/j.jcis.2010.05.02220627257
   PubMed Web of Science ®Google Scholar
• Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63(3):170–183. doi:10.1016/j.addr.2010.10.00820965219
   PubMed Web of Science ®Google Scholar
• Khan S, Chauhan N, Yallapu MM, et al. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Biomaterials. 2015;53:731–743. doi:10.1016/j.biomaterials.2015.02.08225890768
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc National Acad Sci. 2011;108(27):10980–10985. doi:10.1073/pnas.1106634108
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B. 2010;75(1):1–18. doi:10.1016/j.colsurfb.2009.09.001
   PubMed Web of Science ®Google Scholar
• Fang RH, Aryal S, Hu C-MJ, Zhang L. Quick synthesis of lipid− polymer hybrid nanoparticles with low polydispersity using a single-step sonication method. Langmuir. 2010;26(22):16958–16962. doi:10.1021/la103576a20961057
   PubMed Web of Science ®Google Scholar
• Chowdhury P, Nagesh PKB, Hatami E, et al. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. J Colloid Interface Sci. 2019;535:133–148. doi:10.1016/j.jcis.2018.09.07230292104
   PubMed Web of Science ®Google Scholar
• Hatami E, Nagesh PKB, Chowdhury P, et al. Tannic acid-lung fluid assemblies promote interaction and delivery of drugs to lung cancer cells. Pharmaceutics. 2018;10:3. doi:10.3390/pharmaceutics10030111
   Web of Science ®Google Scholar
• Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nature Rev Mol Cell Biol. 2007;8(8):603–612. doi:10.1038/nrm221617609668
   PubMed Web of Science ®Google Scholar
• Saavedra KP, Brebi PM, Roa JCS. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenetics. 2012;4(1):13. doi:10.1186/1868-7083-4-1322938091
   PubMedGoogle Scholar
• Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;87(11):796–802. doi:10.1093/jnci/87.11.7967791229
   PubMed Web of Science ®Google Scholar
• Chichareon S, Herrero R, Muñoz N, et al. Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst. 1998;90(1):50–57. doi:10.1093/jnci/90.1.509428783
   PubMedGoogle Scholar
• Ronco G, Segnan N. HPV testing for primary cervical cancer screening. Lancet. 2007;370(9601):1740–1742. doi:10.1016/S0140-6736(07)61480-917919717
   PubMedGoogle Scholar
• Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(S10):3036–3046. doi:10.1002/cncr.2376418980286
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controlled Release. 2000;65(1):271–284.
   PubMed Web of Science ®Google Scholar
• Yhee JY, Son S, Son S, Joo MK, Kwon IC. The EPR effect in cancer therapy. Cancer Targeted Drug Delivery. 2013;Chapter 23:621–632. doi.10.1007/978-1-4614-7876-8_23
   Google Scholar
• Davis ME, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Rev Drug Discovery. 2008;7(9):771–782. doi:10.1038/nrd261418758474
   PubMed Web of Science ®Google Scholar
• Gupta RC, Paliwal JK, Nityanand S, Asthana OP, Lal J. Centchroman: a new non-steroidal oral contraceptive in human milk. Contraception. 1995;52(5):301–305.8585887
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Zhang S, et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep. 2013;3:2534. doi:10.1038/srep0253423982586
   PubMed Web of Science ®Google Scholar